Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an open-label, multi-site study of AR Blockade with carotuximab in patients who have progressed on androgen receptor signaling inhibitor (ARSI) therapy. This study will begin with a safety assessment in the first 10 subjects (part 1: Safety Lead-in). If the combination is deemed safe, the trial will proceed to the Phase II stage. The purpose of this study is to compare progression free survival (PFS) between patients receiving AR Blockade and AR Blockade + carotuximab using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3. The secondary objectives are to describe adverse events related to the intervention, overall response rate (ORR), proportion of patients resistant to AR blockade that benefit from the addition of carotuximab, and to determine the ORR, radiographic PFS, and biochemical PFS in the overall population.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak prostaty oporny na leczenie hormonalne, u którego PSA rośnie pomimo przyjmowania leków blokujących receptory androgenowe (np. abirateron, enzalutamid, darolutamid).
- •Pacjent poddawany jest kastracji chirurgicznej lub ma niski poziom testosteronu.
- •Pacjent przyjmował co najwyżej dwa różne leki ukierunkowane na receptory androgenowe (z pewnymi wyjątkami).
- •Pacjent nie przyjmował wcześniej chemioterapii (z pewnymi wyjątkami).
- •Pacjent odmawia lub nie może przyjmować chemioterapii taksanowej.
- •Pacjent jest w dobrym stanie ogólnym (według skali ECOG 0-1).
- •Większość dotychczasowych skutków ubocznych leczenia ustąpiła lub jest łagodna.
✗ Disqualifies
- •Obecność przerzutów do mózgu.
- •Nieprawidłowe wyniki badań krwi wskazujące na problemy z wątrobą lub nerkami.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 5, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (3)
City of Hope
Duarte, United States
Cedars-Sinai Medical Center
Los Angeles, United States
Huntsman Cancer Institute and Hospital
Salt Lake City, United States
Trial contact
Clinical Trial Recruitment Navigator
Edwin Posadas, MD FACP
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.